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Background: Surgical resection is considered to be the most effective treatment for localized pulmonary mycotic
infections. However it is also a particularly challenging procedure because it is associated with considerable
mortality and morbidity. Furthermore, hematopoietic disorders usually cause immunosuppression, anemia, and
coagulopathy, which are definite risk factors for surgery. The purpose of this study is to evaluate the surgical
outcomes of pulmonary mycotic infections in hematopoietic disorder patients.
Methods: Between 2011 and 2013, 23 patients underwent surgical treatment for pulmonary mycotic infections at a
single institution. The patients were divided into two groups; Group A (hematopoietic disorder patients, n = 9) and
Group B (n = 14). We retrospectively reviewed medical and radiologic data.
Results: The complex type was more frequent in group A (66.6 %) than in group B (35.7 %). Postoperatively, there
was no mortality. However, morbidity was 22.2 % (2 incomplete expansion) in group A, and 35.6 % (1 prolonged air
leak, 3 bleeding, 1 Bronchopleural fistula) in group B. The difference in morbidity between the groups did not show
any statistical significance (p = 0.657) as well as duration of chest tube drainage, and postoperative hospital stay.
The hematopoietic disorder patients did not impose a risk factor for morbidity and mortality.
Conclusions: Although hematopoietic disorder patients have many surgical risk factors, the surgical treatment of
pulmonary mycotic infections produces very acceptable outcomes in selected cases.
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Hematopoietic disorder is a common designation for
hematopoiesis-related diseases such as aplastic anemia,
myelodysplastic syndrome, and leukemia [1]. Because they
often suffer from immunosuppression, anemia and/or
coagulopathy, patients with this disorder are considered
to be high-risk factor for operation [2]. The immunosup-
pression of these patients could be caused by the under-
lying disease itself, but in many cases it has intensified
after chemotherapy treatment or hematopoietic stem cell
transplantation (HSCT). Fungal infection is more likely
to occur if neutropenia continues after chemotherapy
or HSCT [3]. Fungal disease occurring in this type of* Correspondence: swsung@catholic.ac.kr
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creativecommons.org/publicdomain/zero/1.0/patient is often invasive. Even though it can be initially
diagnosed as localized disease, it can also be detected
as extended disease from the beginning, and when not
treated, mortality has been reported as high as 100 %
due to dissemination [3]. Despite the use of antifungal
agents in the treatment of all patients with invasive
fungal infection, a high rate of mortality has neverthe-
less been reported, ranging from 20 to 40 % [4, 5], and it
is recognized that it is difficult in practice to achieve
complete clearance of fungal infection by antifungal agent
therapy alone [4, 6]. Therefore, the most effective treat-
ment is considered to be surgical clearance of fungus
before HSCT, or if persistent immunosuppression is ex-
pected. However, a decision as to whether to perform
surgery can be difficult due to the high surgical risk.
Various fungi can cause pulmonary mycotic infections,
of which Aspergillus infection is the most frequent [7].ticle distributed under the terms of the Creative Commons Attribution License
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allergic bronchopulomonary aspergillosis (ABPA), asper-
gilloma, and invasive pulmonary aspergillosis (IPA) are
the most commonly found [7]. Among these, aspergil-
loma mainly manifests as a localized disease occurring
in underlying lung disease. IPA outbreaks occur mostly
in immunocompromised patients in the form of a local-
ized or extended disease. In case of aspergilloma, many
reports have confirmed the effectiveness of operative
treatment, though the operative risk is somewhat high
since in many cases the underlying lung disease is severe
[8–10]. However, in the case of IPA, surgical treatment
may be difficult to perform in many cases due to the
high rate of parenchymal invasion. Despite reports of
surgical treatment in cases where it has occurred as a
localized disease, the paucity of such cases has given rise
to considerable uncertainty as to the effectiveness of
surgical treatment [11–14].
The purpose of this study was to evaluate the possi-
bility of surgical treatment for hematopoietic disorder
patients by analyzing the differences in operative risk
and the outcome of surgical treatments between the
general localized pulmonary mycotic infection and the
localized pulmonary mycotic infection occurring in he-
matopoietic disorder patients with high operative risk.
Methods
A retrospective chart review was conducted on 23 pa-
tients who underwent surgical treatment for pulmonary
mycotic infections at Seoul St Mary’s Hospital between
2011 and 2013. In order to evaluate the surgical out-
comes of hematopoietic disorder patients, the patients
were divided into two groups; Group A (hematopoietic
disorder patients, n = 9) and Group B (other patients,
n = 14), and the characteristics and surgical outcomes
of the two groups were compared. The underlying dis-
eases of Group A were: acute myeloid leukemia (AML)
(n = 3), acute lymphoblastic leukemia (ALL) (n = 3), mye-
lodysplastic syndrome (MDS) (n = 1), and aplastic anemia
(n = 2). Those of Group B were: bronchiectasis (n = 4),
old tuberculosis (n = 4), end stage renal disease (n = 1),
liver cirrhosis (n = 1) and non-specific underlying disease
(n = 4).
Open thoracotomy or video-assisted thoracoscopic sur-
gery (VATS) was performed, as was pulmonary resection,
wedge resection, segmentectomy, or lobectomy, depend-
ing on the extent of the disease, as a curative procedure.
In the pre-surgery diagnosis, chest computed tomog-
raphy (CT) scan played the most important role, and
in cases where the ‘halo sign’ or ‘air-crescent sign’ was de-
tected, early surgical resection treatment was performed
when there was a strong suspicion of aspergilloma. How-
ever, in cases when atypical pneumonic consolidation
was detected, surgical treatment was only performedon patients if complete surgical resection became feas-
ible after antifungal agent therapy and in correlation
with the clinical information.
Through histologic examination after surgery, mycotic
infection was confirmed in all cases, there being 21 cases
of aspergillosis and 2 cases of mucormycosis. In cases
of Aspergillus infection, aspergilloma was diagnosed sep-
arately from IPA by confirming bronchopulmonary in-
vasion, vessel invasion, or pulmonary infarction in the
pathologic findings.
Aspergilloma occurred often in the form of a fungus
ball and was categorized into simple and complex types
by the shape of its lesion. Aspergilloma was classified
as the simple type in cases where the surrounding
lung was comparatively normal and the capsule was
thin. It was classified as the complex type if the lung
surrounding the lesion was diseased or the capsule was
thick [15]. However, cases of mucormycosis and IPA
were not classified into the types previously referred to in
existing studies. In this study, the types of Group B pa-
tients (n = 14, all with aspergilloma) were classified in
the same way by applying the pertinent type definition
to the shape of the lesion as shown on the chest CT
image. Out of the 9 patients in Group A, there were
1, 2, and 6 patients who were pathologically diagnosed
as aspergilloma, mucormycosis, and IPA respectively.
A patient with aspergilloma was classified as a simple
type as per the CT image, and 2 patients with mucor-
mycosis were also classified as simple types since both
of them showed a single nodule with the lesion’s sur-
rounding lung parenchyma showing a normal shape on
CT image. Six patients with IPA were classified as com-
plex types since their parenchymal lesion was accom-
panied by infiltration and there were many similarities to
the complex type as per the CT image. Thereafter the
types were matched between the two groups (Fig. 1).
Follow-up data was obtained by review of the out-
patient charts. Chi-square or t test was used for the
comparison of preoperative, intraoperative, and postop-
erative factors of the two groups and a value of P < 0.05
was considered statistically significant. Operative mortal-
ity was defined as in-hospital mortality or those cases in
which the patient died within 30 days following surgery.
The relapse rate after operation was counted and the
all-cause mortality rate was evaluated. Logistic regres-
sion analysis was used to evaluate the risk factor of
postoperative complications. The study was approved
by the institutional Review Board of Seoul St. Mary’s
Hospital (The Catholic University of Korea).Results
There were 9 patients in Group A and 14 patients in
Group B, making a total of 23 patients. The mean age of
Fig. 1 a Simple aspergilloma (Group A) b mucormycosis (Group A) c invasive pulmonary aspergillosis (Group A) d simple aspergilloma (Group B)
e complex aspergilloma (Group B) f complex aspergilloma with empyema (Group B)
Table 1 Patients characteristics
Group A (n = 9) Group B (n = 14) P value
Age 34.7 (±16.6) 49.1 (±15.0) 0.043
Gender
Male 3 (33.3 %) 7 (50 %)
Female 6 (66.6 %) 7 (50 %)
Symptom
Hemoptysis 1 (11.1 %) 7 (50 %)
Fever 6 (66.6 %) 0 (0 %)
Cough 1 (11.1 %) 2 (14.3 %)
None 1 (11.1 %) 5 (35.7 %)
WBC count (×106/L) 5972.2 (±4973.4) 7064.3 (±2720.7) 0.502
ANC count (×106/L) 4335.0 (±4388.9) 4450.7 (±2402.9) 0.935
Hemoglobin (g/dl) 9.8 (±1.4) 12.2 (±2.0) 0.006
Platelet count (×109/L) 112.2 (±72.2) 201.5 (±78.8) 0.012
PEV1 (%) 93.2 (±7.9) 96.3 (±15.1) 0.676
Type
Simple 3 (33.3 %) 9 (64.3 %) 0.147
Complex or IPA 6 (66.6 %) 5 (35.7 %)
WBC white blood cell, ANC absolute neutrophil count, FEV1 forced expiratory
volume in 1 s
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49.1 years (range 20–69). The mean age of Group A was
lower than that of Group B (p = 0.043). Females out-
numbered males in Group A with 6 female patients
(66.6 %) and 3 male patients (33.4 %); while in Group B
the number of males and females was the same with 7
patients (50 %) of each sex. Regarding preoperative
symptoms, in Group A fever was the most common
with 6 instances (66.6 %), and 1 subsequent instance
(11.1 %) of hemoptysis, cough, and subclinical. In
Group B hemoptysis was the most frequent sympton
with 7 instances (50 %) and subsequently there were
5 instances of subclinical (35.7 %) and 2 instances
(14.3 %) of cough. Even though white blood cell (WBC)
counts and absolute neutrophil counts (ANCs) of both
groups in the preoperative complete blood cell count
(CBC) did not show significant differences, both the
hemoglobin and platelet counts of Group A were signifi-
cantly less (9.8(±1.4)g/dl vs 12.2(±2.0)g/dl, p = 0.006),
(112.2(±72.2) × 109/L vs 201.5(±78.8) × 109/L, p = 0.012).
In pulmonary function testing, there were no differences
in the two groups in forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC). In the type
classification by image findings, there were 3 patients
(33.3 %) of simple type and 6 patients (66.6 %) of
complex type in Group A, and there were 9 patients
(64.3 %) of simple type and 6 patients (35.7 %) of
complex type in Group B. Even though the complex
type ratio was higher in Group A, it was not statisti-
cally significant (p = 0.147) (Table 1).
Before operation, all patients in Group A were treated
with antifungal agents, but Group B patients were not.Antifungal agents used in Group A were amphotericin B
for 4 patients, IV voriconazole for 2 patients, and oral
antifungal agent (fluconazole, itraconazole, posacona-
zole) for 3 patients, with the average period of treatment
44.3 days (16–147 days). Six patients (66.7 %) showed
a partial response such as reduction of infiltration or
size in the surrounding lung (Fig. 2).
Fig. 2 Size reduction after antifungal medical treatment. a Invasive pulmonary aspergillosis of which diameter was 7 cm in the right upper lobe.
b Size reduction to 5 cm after administration of intravenous amphotericin B for 24 days
Table 3 Surgical outcomes
Group A Group B P value
Operation time (min) 118.4 (±48.3) 160.9 (±81.3) 0.174
Blood loss (ml) 452.2 (±640.5) 309.2 (±221.2) 0.535
Air leak (days) 0 0.86 (±2.2) 0.171
Chest tube drainage 3.2 (±1.8) 5.0 (±3.2) 0.104
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range of the disease and the operation was performed
for complete resection of the localized lesion. In the case
of Group A, 2 procedures were performed on 3 patients
out of the 9, making a total of 12 procedures in all. In
the case of Group B, 2 procedures were performed on
4 patients out of 14, making a total of 18 procedures
in all. In both groups lung wedge resection was the
most frequently performed procedure with segmen-
tectomy and lobectomy next in frequency. In cases of
simple type, pulmonary lesions were easy to resect
without 1 case of enucleation performed on a right
upper lobe (RUL) nodule close to a RUL bronchus in
Group B. However, in cases of complex type including
invasive aspergillosis, pulmonary resections were diffi-
cult due to severe adhesion, fragility of lung parench-
yme, and unresectable inflammatory lymph nodes. In
some cases of complex type, other procedures were
needed: 1 case of myocardial abscess drainage per-
formed along with lung wedge resection in Group A,
1 case of cavernostomy performed on a fungus ball
with chronic pleural empyema in Group B. The spectrum
of surgical procedures did not differ significantly between
the two groups (p = 0.500) (Table 2).
There were no statistically significant differences in
duration of operation and of the volume of blood loss
during the operation between the two groups, and
there were no statistically significant differences either
in average duration of chest tube drainage (3.2(±1.8)Table 2 Surgical procedures
Group A (n = 12) Group B (n = 18) P value
Procedure 0.500
Lobectomy 4 (33.3 %) 2 (11.1 %)
Segmentectomy 1 (8.3 %) 3 (16.7 %)
Wedge resection 6 (50.0 %) 11 (61.1 %)
Other procedures 1 (8.3 %) 2 (11.1 %)
VATS 5 (55.6 %) 11 (78.6 %) 0.363
VATS video assisted thoracoscopic surgerydays vs 5.0(±3.2) days, p = 0.104) and length of hospital
stay (9.2(±5.0) days vs 11.9(±11.1) days, p = 0.512) after
operation. There was no postoperative mortality. Post-
operative complications occurred in 7 patients (30.4 %)
in total. In Group A, complications occurred in 2 pa-
tients (22.2 %) in total and in both cases it was in-
complete reexpansion of lung, with both cases
recovering after a few months following operation. In
Group B complications occurred in 5 patients (35.6 %) in
total; with 1 patient with 8 days of prolonged air leak, 2
patients with postoperative bleeding with pleural blood
drainage over 1000 ml within 24 h after operation
(and who recovered after transfusion without reopera-
tion), 1 patient with delayed hemothorax (which oc-
curred on the 12th day after operation and who
recovered after intercostal artery embolization and pleural
drainage), and finally 1 patient with bronchopleural fistula
(BPF) after cavernostomy. The BPF patient was dis-
charged from hospital with open chest tube drainage
under careful monitoring and on the 48th day after oper-
ation, the BPF closed spontaneously and the drainage
tube was removed. After that, he was monitored forperiod (days)
Postoperative hospital
stay (days)
9.2 (±4.9) 11.9 (±11.1) 0.512
Morbidity 2 (22.2 %) 5 (35.6 %) 0.657
Incomplete reexpansion 2 (22.2 %) 0 (0 %)
Prolonged air leaks 0 (0 %) 1 (7.1 %)
Hemorrhage 0 (0 %) 3 (21.4 %)
BPF 0 (0 %) 1 (7.1 %)
30-days mortality (%) 0 0
BPF bronchopleural fistula
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(Table 3).
Logistic Regression analysis was used to evaluate the
risk factors for complications. After univariable ana-
lysis, division of groups was not risk factors for com-
plication incidence (p = 0.318) and analysis found that
the possibility of the complication occurrence was higher
in cases where the sex of the patient was male (OR = 8.25,
p = 0.036) and the range of the operation was wide (wedge
resection < segmentectomy < lobectomy, OR = 3.012, p =
0.029). In multivariate analysis none of the factors, in-
cluding the division of groups, showed statistic signifi-
cance (Table 4).
Mean follow-up period was 692.5 days (±351.2). During
follow-up periods, 2 patients in Group A died 114 days
and 187 days after operation respectively, and both of
them died of complications (sepsis, graft-versus-host
disease) after HSCT. During the follow-up period, no
recurrence of fungal disease was observed in any patients.Discussion
Although pulmonary mycotic infections can be caused
by various types of fungi, aspergillosis and mucormycosis
can be said to be the typical ones which cause localized
pulmonary mycotic infections [16]. It is known that while
aspergillosis can cause disease in both the immunocom-
petent patient and the immnucompromised patient,
mucormycosis can cause disease only in the immuno-
compromised patient [17]. In this study, 21 of 23 pa-
tients were diagnosed with aspergillosis and 2 patients
were diagnosed with mucormycosis.Table 4 Risk factors for postoperative morbidity by univariate
logistic regression analysis
Risk factors Odds ratio 95 % confidence
interval
P value
Sex (male) 8.250 1.154–59.003 0.036
Age 0.997 0.947–1.050 0.906
Group (Group B) 2.625 0.395–17.458 0.318
Operation duration (min) 1.009 0.996–1.022 0.180
Intraoperative blood loss (ml) 1.000 0.998–1.002 0.910
ANC 1.000 1.000–1.000 0.632
Hemoglobin (g/dl) 1.431 0.900–2.275 0.130
Platelet count (×109/L) 1.001 0.991–1.012 0.778
FEV1 (%) 0.960 0.886–1.041 0.320
Type (complex) 2.500 0.428–14.607 0.309
Extent of procedure 3.012 1.122–8.089 0.029
VATS 0.606 0.097–3.788 0.592
ANC absolute neutrophil count, FEV1 forced expiratory volume in 1 s,
VATS video assisted thoracoscopic surgeryWhen aspergillosis occurs as a localized lung disease,
aspergilloma is a typical picture; it also occurs some-
times in IPA as a localized lung disease.
In cases of aspergilloma, hemoptysis is the most fre-
quent symptom. If the patient is immunocompetent,
antifungal agent is of no use and only surgical treat-
ment is known to be effective treatment [9, 18]. Although
Jewkes el al. reported that it would be better to apply
surgical treatment only if hemoptypsis was detected, due
to the high morbidity and mortality rate of surgery [19],
many studies have reported that surgical treatment could
increase the survival rate even if there were no symptoms,
since in recent years the severity of the underlying
lung disease has been low in many cases and surgical
outcomes were getting better along with the develop-
ment of operative techniques [20, 21]. Therefore, it is
generally considered best to perform surgical treatment
if there are symptoms, and if there are no symptoms,
to perform surgical treatment only if the patient’s gen-
eral condition can withstand pulmonary resection [7, 22].
In the case of IPA, since it is often not only invasive
into surrounding tissue but also disseminated systemic-
ally through the whole body, initial treatment with anti-
fungal agents is recommended. However mortality is
known to be high even if treated with antifungal agents
[5, 23, 24]. Even though a few studies have reported
that the surgical treatment of IPA increased the sur-
vival rate, those studies are now considered inappro-
priate in evaluating current surgical outcomes since most
of those studies evaluated patients at single centers
and over a long period of time in the considerable
past [11–14, 21], and surgical treatment methods have
developed since then. However, in this study we evalu-
ated patients treated in a recent comparatively short
period of 3 years, and treated by recent surgical tech-
niques at a single center, so we believe the comparison
of surgical outcomes in this study would be more real-
istic than those of the existing studies.
While mucormycosis also has a clinical course similar
to IPA, it can proceed to disseminated disease in im-
munocompromised patients and it has been reported
that the mortality is very high when treated only with
medical treatment [17]. There have been reports that
surgical treatment increased survival rates in cases of
localized pulmonary mucormycosis [16, 25]. However,
since the disease incidence was very low and only a
few studies were reported, there has been no certain
established treatment. In this study, we evaluated 2
patients with the simple type of lesion and who were
treated with resection (wedge resection). They were
discharged from hospital without complications and
without relapse for a mean 661.5 days of follow-up.
Aspergilloma can be divided into simple and com-
plex types [15], and in the case of the complex type,
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operative risk since the lung around the lesion is ab-
normal. In the case of IPA, even though there are
some cases which look similar to the simple type on
radiologic imaging, in many cases they are similar to
the complex type since the disease infiltrates into the
surrounding lung parenchyma, but IPA has not been
divided into simple and complex types. In this study,
infiltration into the surrounding lung was classified as
the complex type, based on imaging study findings. In
this way, both Group A and B could be divided into
simple and complex types. With this division, we evalu-
ated the distribution of types in both groups and found
there was no statistical difference between the two groups.
In addition, there was no difference in pulmonary func-
tion between the two groups and there was also no
significant difference in the range of the surgical pro-
cedure. Therefore both groups were considered under
about the same conditions and under these conditions
it was considered meaningful to compare the surgical
outcome.
In Group A, there were 6 cases of disease occurrence
after chemotherapy, 1 case after immunotherapy, and
2 cases after HSCT. All of them were considered to
have occurred after having gone through a neutropenic
phase. Most of them had underlying conditions such
as neutropenia, anemia, and thrombocytopenia. Delay-
ing the operation, or giving blood transfusion were mea-
sures used to maintain the platelet count over 50(×109/L)
and the hemoglobin over 10.0 g/dl for the safety of
operation. Nevertheless, the preoperative hemoglobin
and platelet counts of Group A were significantly lower
than those of Group B. Even though the average intraop-
erative blood loss of Group A (452.2 ml) was more than
that of Group B (309.2 ml), there was no statistically
significant difference. In addition in both groups there
was no case of reoperation due to postoperative bleeding.
Among Group A patients, there was 1 case in which
it was considered difficult to perform sugical resection
due to too severe infiltration into the surrounding lung
at the initial stage, but lung infiltration reduced signifi-
cantly after use of antifungal agent, making it possible
to perform pulmonary resection; and 6 patients out of
total 9 showed a partial response so that it was possible to
reduce the range of operation. In the case of IPA, studies
have reported voriconazole to be most effective antifungal
agent [2, 4, 6]. However, in this study, voriconazole was
used only for 2 patients and amphotericin B for 4 pa-
tients, and oral antifungal agents (fluconazole, itracona-
zole, posaconazole) for the remaining 3 patients.
It has been reported in many studies that the surgical
treatment of aspergilloma resulted in 20–30 % of mor-
bidity and 5–10 % of mortality [7], and although there
have not been many studies in the case of IPA, Nebikeret al. have reported 15–23 % morbidity and 7 % mortal-
ity [13]. In this study, morbidity was 22.2 and 35.6 % in
Group A and B respectively and there was no significant
difference from that of the existing studies. However
in this study there was neither any case of major com-
plication requiring management (like reoperation) nor
any 30-day mortality. It could not be said that surgical
treatment of hematopoietic disorder patient had more
operative risk since the division of groups proved to be
meaningless in the complications risk factor evaluation.
The limitations of this study were as follows. First,
it was retrospective study. Second, a relatively small
number of patients were included. Third, only selected
patients with hematopoietic disorder underwent surgery;
in other words, surgery was performed neither in cases
where a higher level of surgery over pneumonectomy
was required due to severe disseminated disease or
wide lung infiltration, nor was it performed in cases of
graft versus host disease after chemotherapy or HSCT.
Surgery was not performed either if high risk factors
of general anesthesia existed, namely renal failure, hep-
atic failure, sepsis, etc. However, surgery was performed
as extensively as possible in case pulmonary resection
was considered possible.Conclusions
In summary, the surgical treatment of localized pulmon-
ary mycotic infection can achieve good surgical out-
comes if complete resection is possible in hematopoietic
disorder patients who have had immunosupression, co-
agulopathy, anemia and severe pulmonary infiltration.
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